IP Library Granted Patent US 11,725,240
Granted Patent B2
US 11,725,240 · App. 17/152,007 · Granted Aug 15, 2023

Functional ligands to opioids and opioid derivatives

Inventors: Jasmine Kaur (Pearland, TX); Rafal Drabek (Houston, TX); George W. Jackson (Pearland, TX); Robert Batchelor (Pearland, TX); Alexander Chiu (Pearland, TX)
Assignee: BASE PAIR BIOTECHNOLOGIES, INC.
C12Q1/6874C12N15/1048C12N15/115C12Q1/6806C12Q1/6837C12Q1/6848C12Q1/6876C40B30/04C12N2310/16C12N2330/31
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,725,240
App. No.
17/152,007
Granted
Aug 15, 2023
Kind
B2
Abstract

The present invention relates functional ligands to target molecules, particularly to functional nucleic acids and modifications thereof, and to methods for simultaneously generating, for example, numerous different functional biomolecules, particularly to methods for generating numerous different functional nucleic acids against multiple target molecules simultaneously. The present invention further relates to functional ligands which bind with affinity to target molecules, such as opioids and opioid derivatives.

Claims (10)

1. An artificial ligand binding to acetyl fentanyl comprising a non-naturally occurring nucleic acid sequence of under 40 nucleotides in length having greater than 90% sequence identity to a sequence selected from the group consisting of SEQ ID Nos. 1-10.

2. The artificial ligand of claim 1 wherein at least one nucleotide is substituted with a non-natural analog.

3. The artificial ligand of claim 1 further comprising an appended 5′-sequence selected from the group consisting of SEQ ID Nos. 294-295.

4. The artificial ligand of claim 1 further comprising an appended 3′-sequence selected from the group consisting of SEQ ID Nos. 294-295.

5. The artificial ligand of claim 1 further comprising an appended 5′-sequence and an appended 3′-sequence selected from the group consisting of SEQ ID Nos. 294-295.

6. An artificial ligand binding to acetyl fentanyl comprising a non-naturally occurring nucleic acid sequence having 100% sequence identity to a sequence selected from the group consisting of SEQ ID Nos. 1-10.

7. The artificial ligand of claim 6 wherein at least one nucleotide is substituted with a non-natural analog.

8. The artificial ligand of claim 6 wherein said non-naturally occurring nucleic acid sequence is appended with a 5′-sequence selected from the group consisting of SEQ ID Nos. 294-295.

9. The artificial ligand of claim 6 wherein said non-naturally occurring nucleic acid sequence is appended with a 3′-sequence selected from the group consisting of SEQ ID Nos. 294-295.

10. The artificial ligand of claim 6 wherein said non-naturally occurring nucleic acid sequence is appended with a 5′-sequence and a 3′-sequence selected from the group consisting of SEQ ID Nos. 294-295.

Continuity (21)
Continuation In Part 16677433 · Nov 7, 2019
Continuation In Part 16262769 · Jan 30, 2019
Continuation In Part 16262777 · Jan 30, 2019
Continuation 15893532 · Feb 9, 2018
Continuation In Part 15811578 · Nov 13, 2017
Continuation In Part 14297484 · Jun 5, 2014
Continuation In Part 13748566 · Jan 23, 2013
Continuation In Part 13493996 · Jun 11, 2012
Continuation In Part 12683429 · Jan 7, 2010
Provisional Application 62962109 · Jan 16, 2020
Provisional Application 62767436 · Nov 14, 2018
Provisional Application 62666263 · May 3, 2018
Provisional Application 62624068 · Jan 30, 2018
Provisional Application 62624068 · Jan 30, 2018
Provisional Application 62460786 · Feb 18, 2017
Provisional Application 62456847 · Feb 9, 2017
Provisional Application 62421153 · Nov 11, 2016
Provisional Application 61917665 · Dec 18, 2013
Provisional Application 61831334 · Jun 5, 2013
Provisional Application 61495976 · Jun 11, 2011
Related Publication 20210348226A1 · Nov 11, 2021